Nitazoxanide inhibits paramyxovirus replication by targeting the Fusion protein folding: Role of glycoprotein-specific thiol oxidoreductase ERp57

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Piacentini, Sara ^a   La Frazia, Simone ^a   Riccio, Anna ^a   Pedersen, Jens Z ^a   Topai, Alessandra ^a   Nicolotti, Orazio ^b   Rossignol, Jean Francois ^c   Santoro, M Gabriella ^a,d  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NITAZOXANIDE; OXIDOREDUCTASE; PDIA3 PROTEIN, HUMAN; PROTEIN DISULFIDE ISOMERASE; THIAZOLE DERIVATIVE; TIZOXANIDE; VIRUS FUSION PROTEIN;

A-549 CELL LINE; ANIMAL; BINDING SITE; CHEMISTRY; DRUG EFFECT; HUMAN; METABOLISM; PARAMYXOVIRIDAE; PARAMYXOVIRUS INFECTION; PHYSIOLOGY; PROTEIN FOLDING; PROTEIN TRANSPORT; VIRUS REPLICATION;

A549 CELLS; ANIMALS; BINDING SITES; HUMANS; OXIDOREDUCTASES; PARAMYXOVIRIDAE; PARAMYXOVIRIDAE INFECTIONS; PROTEIN DISULFIDE-ISOMERASES; PROTEIN FOLDING; PROTEIN TRANSPORT; THIAZOLES; VIRAL FUSION PROTEINS; VIRUS REPLICATION;

EID: 85049772079     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-28172-9     Document Type: Article

References (54)

1. Lamb, R. A. &Park, G. D. Paramyxoviridae, 6th edition [Knipe, D. M. &Howley, P. M. (eds)]. Fields Virology, Chapter 33, 957-995 (Wolters Kluwer/Lippincott Williams &Wilkins, 2013).
2. Aguilar, H. C. &Lee, B. Emerging paramyxoviruses: molecular mechanisms and antiviral strategies. Expert Rev. Mol. Med. 13, e6 (2011).
3. Jardetzky, T. S. &Lamb, R. A. Activation of paramyxovirus membrane fusion and virus entry. Curr. Opin. Virol. 5, 24-33 (2014).
4. Krzyzaniak, M. A., Zumstein, M. T., Gerez, J. A., Picotti, P. &Helenius, A. Host cell entry of respiratory syncytial virus involves macropinocytosis followed by proteolytic activation of the F protein. PLoS Pathog. 9, e1003309 (2013).
5. Tamura, T., Yamashita, T., Segawa, H. &Taira, H. N-linked oligosaccharide chains of Sendai virus fusion protein determine the interaction with endoplasmic reticulum molecular chaperones. FEBS Lett. 513, 153-158 (2002).
6. Segawa, H., Kato, M., Yamashita, T. &Taira, H. The roles of individual cysteine residues of Sendai virus fusion protein in intracellular transport. J. Biochem. 123, 1064-1072 (1998).
7. Ellgaard, L. &Ruddock, L. W. The human protein disulphide isomerase family: substrate interactions and functional properties. EMBO Rep. 6, 28-32 (2005).
8. Fox, L. M. &Saravolatz, L. D. Nitazoxanide: a new thiazolide antiparasitic agent. Clin. Infect. Dis. 40, 1173-1180 (2005).
9. Rossignol, J. F. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res. 110, 94-103 (2014).
10. Rossignol, J. F., La Frazia, S., Chiappa, L., Ciucci, A. &Santoro, M. G. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J. Biol. Chem. 284, 29798-29808 (2009).
11. Haffizulla, J. et al. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect. Dis. 14, 609-618 (2014).
12. Rossignol, J. F., Elfert, A., El-Gohary, Y. &Keeffe, E. B. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 136, 856-862 (2009).
13. La Frazia, S. et al. Thiazolides, a new class of antiviral agents effective against rotavirus infection, target viral morphogenesis, inhibiting viroplasm formation. J. Virol. 87, 11096-11106 (2013).
14. Rossignol, J. F., Abu-Zekry, M., Hussein, A. &Santoro, M. G. Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial. Lancet 368, 124-129 (2006).
15. Morito, D. &Nagata, K. Pathogenic hijacking of ER-associated degradation: is ERAD Flexible? Mol. Cell. 59, 335-344 (2015).
16. Rossi, A. et al. The proteasome inhibitor bortezomib is a potent inducer of zinc finger AN1-type domain 2a gene expression: role of heat shock factor 1 (HSF1)-heat shock factor 2 (HSF2) heterocomplexes. J. Biol. Chem. 289, 12705-12715 (2014).
17. Iwata, S. et al. Assignment of disulfide bridges in the fusion glycoprotein of Sendai virus. J. Virol. 68, 3200-3206 (1994).
18. Jessop, C. E. et al. ERp57 is essential for efficient folding of glycoproteins sharing common structural domains. EMBO J. 26, 28-40 (2007).
19. Hebert, D. N. &Molinari, M. In and out of the ER: protein folding, quality control, degradation, and related human diseases. Physiol. Rev. 87, 1377-1408 (2007).
20. Mezghrani, A. et al. Manipulation of oxidative protein folding and PDI redox state in mammalian cells. EMBO J. 20, 6288-6296 (2001).
21. Braakman, I. &van Anken, E. Folding of viral envelope glycoproteins in the endoplasmic reticulum. Traffic. 1, 533-539 (2000).
22. Gaucci, E. et al. Analysis of the interaction of calcitriol with the disulfide isomerase ERp57. Sci. Rep. 6, 37957 (2016).
23. Tian, G., Xiang, S., Noiva, R., Lennarz, W. J. &Schindelin, H. The crystal structure of yeast protein disulfide isomerase suggests cooperativity between its active sites. Cell 124, 61-73 (2006).
24. Kozlov, G. et al. Crystal structure of the bb' domains of the protein disulfide isomerase ERp57. Structure 14, 1331-1339 (2006).
25. Müller, J., Naguleswaran, A., Müller, N. &Hemphill, A. Neospora caninum: functional inhibition of protein disulfide isomerase by the broad-spectrum anti-parasitic drug nitazoxanide and other thiazolides. Exp. Parasitol. 118, 80-88 (2008).
26. Henrich, S. et al. Computational approaches to identifying and characterizing protein binding sites for ligand design. J. Mol. Recognit. 23, 209-219 (2010).
27. Cheng, A. C. et al. Structure-based maximal affinity model predicts small-molecule druggability. Nat. Biotechnol. 25, 71-75 (2007).
28. Senkowski, W. et al. Three dimensional cell culture based screening identifies the anthelminthic drug nitazoxanide as a candidate for treatment of colorectal cancer. Mol. Cancer Therapeut. 14, 1504-1516 (2015).
29. Senkowski, W. et al. Large-scale gene expression screening in three-dimensional cell cultures identifies context-dependent drug responses. Cell Chem. Biol. 23, 1428-1438 (2016).
30. Braakman, I., Helenius, J. &Helenius, A. Role of ATP and disulphide bonds during protein folding in the endoplasmic reticulum. Nature 356, 260-262 (1992).
31. Braakman, I., Hoover-Litty, H., Wagner, K. R. &Helenius, A. Folding of influenza hemagglutinin in the endoplasmic reticulum. J. Cell Biol. 114, 401-411 (1991).
32. Mirazimi, A. &Svensson, L. ATP is required for correct folding and disulfide bond formation of rotavirus VP7. J. Virol. 74, 8048-8052 (2000).
33. Drexler, J. F. et al. Bats host major mammalian paramyxoviruses. Nat. Commun. 3, 796 (2012).
34. Vigant, F., Santos, N. C. &Lee, B. Broad-spectrum antivirals against viral fusion. Nat. Rev. Microbiol. 13, 426-437 (2015).
35. Song, A. S. et al. Immobilization of the N-terminal helix stabilizes prefusion paramyxovirus fusion proteins. Proc. Natl. Acad. Sci. USA 113, E3844-3851 (2016).
36. Wen, X. et al. Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus. Nat. Microbiol. 2, 16272 (2017).
37. Corti, D. et al. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature 501, 439-443 (2013).
38. Soldà, T., Garbi, N., Hämmerling, G. J. &Molinari, M. Consequences of ERp57 deletion on oxidative folding of obligate and facultative clients of the calnexin cycle. J. Biol. Chem. 281, 6219-6226 (2006).
39. Santoro, M. G., Benedetto, A., Carruba, G., Garaci, E. &Jaffe, B. M. Prostaglandin A compounds as antiviral agents. Science 209, 1032-1034 (1980).
40. Belardo, G., Cenciarelli, O., La Frazia, S., Rossignol, J. F. &Santoro, M. G. Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro. Antimicrob. Agents Chemother. 59, 1061-1069 (2015).
41. Santoro, M. G., Amici, C., Elia, G., Benedetto, A. &Garaci, E. Inhibition of virus protein glycosylation as the mechanism of the antiviral action of prostaglandin A in Sendai virus-infected cells. J. Gen. Virol. 70, 789-800 (1989).
42. Amici, C. et al. Inhibition of viral protein translation by indomethacin in vesicular stomatitis virus infection: role of eIF2α kinase PKR. Cell Microbiol. 17, 1391-1404 (2015).
43. Rossi, A. et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 403, 103-108 (2000).
44. Coccia, M., Rossi, A., Riccio, A., Trotta, E. &Santoro, M. G. Human NF-kB repressing factor acts as a stress-regulated switch for ribosomal RNA processing and nucleolar homeostasis surveillance. Proc. Natl. Acad. Sci. USA 114, 1045-1050 (2017).
45. Jasuja, R. et al. Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents. J. Clin. Invest. 122, 2104-2113 (2012).
46. Bekendam, R. H. et al. A substrate-driven allosteric switch that enhances PDI catalytic activity. Nat. Commun. 7, 12579 (2016).
47. Trnková, L., Ricci, D., Grillo, C., Colotti, G. &Altieri, F. Green tea catechins can bind and modify ERp57/PDIA3 activity. Biochim. Biophys. Acta 1830, 2671-2682 (2013).
48. Dong, G., Wearsch, P. A., Peaper, D. R., Cresswell, P. &Reinisch, K. M. Insights into MHC class I peptide loading from the structure of the tapasin-ERp57 thiol oxidoreductase heterodimer. Immunity 30, 21-32 (2009).
49. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 28, 849-857 (1985).
50. Cruciani, G., Pastor, M. &Guba, W. VolSurf: a new tool for the pharmacokinetic optimization of lead compounds. Eur. J. Pharm. Sci. 11, S29-S39 (2000).
51. Alberga, D. et al. A new gating site in human aquaporin-4: Insights from molecular dynamics simulations. Biochim. Biophys. Acta 1838, 3052-3060 (2014).
52. Mangiatordi, G. et al. Challenging AQP4 druggability for NMO-IgG antibody binding using molecular dynamics and molecular interaction fields. Biochim. Biophys. Acta 1848, 1462-1471 (2015).
53. Schrödinger Release 2016-4 Maestro, Version 11.0, Schrödinger, LLC, New York, NY (2016).
54. Banks, J. L. et al. Integrated modeling program, applied chemical theory (IMPACT). J. Comput. Chem. 26, 1752-1780 (2005).